HomeScienceSynthetic Microparticles Drive 100-Day
SCIENCE

Synthetic Microparticles Drive 100-Day CAR T-Cell Growth

Bioengineers engineered programmable microparticles that stimulate human CAR T cells ex vivo, achieving sustained expansion for over 100 days without genetic rewiring.

WHAT YOU NEED TO KNOW
  • CAREp microparticles sustained human a-EGFR CAR-T cell expansion for over 100 days ex vivo.
  • The system achieved up to 1018-fold cumulative expansion across 4-1BBζ and CD28ζ constructs.
  • The platform outperformed tumor-cell and CD3/CD28-Dynabeads stimulation methods.
  • Inventors from Drexel University and UCSF hold pending patent applications for the technology.

Researchers have engineered synthetic microparticles that sustain the expansion of human chimeric antigen receptor T cells for more than 100 days outside the body, according to a study published in Nature Communications.

The platform, designated CAREp, consists of programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies. Designed to repeatedly stimulate human CD8+ CAR-T cells ex vivo, the particles sustained the growth of a-EGFR CAR-T cells across both 4-1BBζ and CD28ζ constructs. The approach achieved up to 1018-fold cumulative expansion, surpassing benchmark stimulation methods using tumor cells or CD3/CD28-Dynabeads without requiring genetic rewiring.

T cells cultured with the particles maintained effector function and mitochondrial fitness throughout the expansion period. The cells demonstrated clonal enrichment, delayed exhaustion, and initially preserved memory-associated progenitor states. The stimulation also transiently activated telomerase, which delayed telomere attrition.

Early transcriptomic profiling revealed coordinated activation of DNA repair, chromatin remodeling, telomere maintenance, and mitochondrial function. At the same time, the particles restricted signaling programs tied to cell differentiation. The authors reported that nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states.

Investigators from Drexel University and the University of California, San Francisco led the research alongside collaborators at Stanford University, the University of Pennsylvania, Thomas Jefferson University, and Brown University. The work received support from National Institutes of Health Grant 1U54CA244438, the Coulter-Drexel Translational Research Partnership Program, the Margaret Q. Landenberger Research Foundation, and the Drexel University Startup Fund. Several study authors, including Xiao Huang, Tejal A. Desai, Wendell A. Lim, and Jasper Z. Williams, are inventors on pending patents covering the technology.

Xentir Media
Xentir Media NewsroomSource-backed AI and technology coverage, drafted by Xentir's automated editorial system under fixed human-set rules. See our editorial policy and AI usage policy.
J
Jomon · Founder & EditorFounder and editor of Xentir Media. Sets the editorial rules the newsroom system runs under, and is accountable for its corrections. About Jomon · [email protected]
The Xentir Brief
The developments worth knowing — one useful email.
Get the Brief →